HomeCompareCPHRF vs ADC

CPHRF vs ADC: Dividend Comparison 2026

CPHRF yields 15.38% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $124.2K in total portfolio value· pulled ahead in Year 7
10 years
CPHRF
CPHRF
● Live price
15.38%
Share price
$13.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.8K
Annual income
$3,973.98
Full CPHRF calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — CPHRF vs ADC

📍 ADC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCPHRFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CPHRF + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CPHRF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CPHRF
Annual income on $10K today (after 15% tax)
$1,307.69/yr
After 10yr DRIP, annual income (after tax)
$3,377.88/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $65,299.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CPHRF + ADC for your $10,000?

CPHRF: 50%ADC: 50%
100% ADC50/50100% CPHRF
Portfolio after 10yr
$116.9K
Annual income
$42,385.64/yr
Blended yield
36.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

CPHRF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
8.2
Piotroski
8/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CPHRF buys
0
ADC buys
0
No recent congressional trades found for CPHRF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCPHRFADC
Forward yield15.38%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$54.8K$178.9K
Annual income after 10y$3,973.98$80,797.29
Total dividends collected$26.9K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: CPHRF vs ADC ($10,000, DRIP)

YearCPHRF PortfolioCPHRF Income/yrADC PortfolioADC Income/yrGap
1$12,238$1,538.46$10,990$580.36+$1.2KCPHRF
2$14,855$1,759.66$12,301$860.26+$2.6KCPHRF
3$17,891$1,996.12$14,104$1,298.62+$3.8KCPHRF
4$21,390$2,246.80$16,691$2,008.16+$4.7KCPHRF
5$25,398$2,510.50$20,580$3,205.09+$4.8KCPHRF
6$29,961$2,785.88$26,754$5,330.02+$3.2KCPHRF
7← crossover$35,130$3,071.47$37,196$9,345.14$2.1KADC
8$40,955$3,365.74$56,244$17,523.09$15.3KADC
9$47,489$3,667.11$94,286$35,736.21$46.8KADC
10$54,787$3,973.98$178,949$80,797.29$124.2KADC

CPHRF vs ADC: Complete Analysis 2026

CPHRFStock

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Full CPHRF Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this CPHRF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CPHRF vs SCHDCPHRF vs JEPICPHRF vs OCPHRF vs KOCPHRF vs MAINCPHRF vs NNNCPHRF vs EPRTCPHRF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.